29 March 2022 | News
Telix's lead product, Illuccix (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA)
Image credit: shutterstock
Australia-based Telix Pharmaceuticals has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuccix (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the United Kingdom (U.K.) and the Republic of Ireland.
Under the terms of the agreement, Xiel, a specialist distributor of Nuclear Medicine, Radiotherapy and Diagnostic Radiology technologies across the U.K. and Ireland will be the exclusive commercial distributor of Illuccix in the U.K. (a top 5 European market by GDP) and the Republic of Ireland for a period of three years from the national approval date.
Xiel replaces Curium as Telix's exclusive distribution partner in the U.K. and the Republic of Ireland.